Suchergebnisse - "Roeker, Lindsey E"

PubPharm (5)

1

Adding Umbralisib and Ublituximab (U2) to Ibrutinib in Patients with CLL : A Phase II Study of an MRD-Driven Approach

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2022

von Roeker, L. | Feldman, T. | Soumerai, J. | +23

2

Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma : a multicentre, single-arm, phase 2 trial

enthalten in: The Lancet. Haematology | 2021

von Soumerai, J. | Mato, A. | Dogan, A. | +43

CommentIn: Lancet Haematol. 2021 Dec;8(12):e864-e865. - PMID 34826404

3

BTK Inhibitors in Cancer Patients with COVID-19 : "The Winner Will be the One Who Controls That Chaos" (Napoleon Bonaparte)

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2020

von Chong, E. | Roeker, L. | Shadman, M. | +3

4

Hypertension in Patients Treated With Ibrutinib for Chronic Lymphocytic Leukemia

enthalten in: JAMA network open | 2019

von Roeker, L. | Sarraf Yazdy, M. | Rhodes, J. | +4

5

Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trial

enthalten in: American journal of hematology | 2018

von Mato, A. | Roeker, L. | Allan, J. | +27

1
[1]